Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 858

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 858
---
 whether civil, criminal, administrative or other (including but not limited to, liabilities under contract, tor and statute or any applicable foreign law or regulation and all reasonable legal and other costs and expenses properly payable) which they or any of them shall or may incur or sustain by or reason of (i) any act done or alleged to be done, concurred or alleged to be concurred in or omitted or alleged to be omitted in or about the execution of their duty, or alleged duty; (ii) serving as a member of our board of directors or member of our executive management; or (iii) serving at our request as director, officer, or employee or agent of another company, partnership, trust or other enterprise. We may enter into indemnification agreements with each of our directors, the form of which has been filed as an exhibit to this proxy statement/prospectus. Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. II-1

Item 21. Exhibits and Financial Statements Schedules (a) Exhibits The following exhibits are filed as part of this Registration Statement:

| Exhibit 
 Number  
 2.1     
 2.2     |     | Description of Document                                                                                                                                                                                                                                                         
 Agreement and Plan of Merger, dated as of November 4, 2024, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included as Annex A to the proxy statement/prospectus forming a part of this Registration Statement).                     
 Amendment No. 1 to Agreement and Plan of Merger, dated as of January 30, 2025, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included in Annex A to the proxy statement/prospectus forming a part of this Registration Statement).  |
|:--------|:----|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.3     |     | Amendment No. 2 to Agreement and Plan of Merger, dated as of February 17, 2025, by and among NLS Pharmaceutics Ltd., NLS Pharmaceut